Active Biotech AB
Active Biotech AB (publ), a biotechnology company, engages in the research, development, and production of pharmaceutical products in Sweden. It is developing Tasquinimod, a small molecule immunomodulator, which is in Phase Ib/IIa clinical trial to treat relapsed refractory multiple myeloma; Laquinimod, a mechanism which is in phase 1 for the treatment of severe inflammatory eye diseases, such as… Read more
Active Biotech AB (ACTI) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -1.600x
Based on the latest financial reports, Active Biotech AB (ACTI) has a cash flow conversion efficiency ratio of -1.600x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-7.20 Million) by net assets (Skr4.50 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Active Biotech AB - Cash Flow Conversion Efficiency Trend (2002–2024)
This chart illustrates how Active Biotech AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Active Biotech AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Active Biotech AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
P/F Atlantic Petroleum
CO:ATLA-DKK
|
0.006x |
|
Agrogeneration
PA:ALAGR
|
-0.030x |
|
Discount Investment Corp Ltd
TA:DISI
|
0.018x |
|
FIN Resources Ltd
AU:FIN
|
-0.030x |
|
CEL.AS.SEC.HLD.NEW HD-02
F:CE0
|
N/A |
|
STONE ONE PUBLIC COMPANY LIMITED
BK:STX
|
0.021x |
|
INGERSOLL-RAND (2IS.SG)
STU:2IS
|
0.171x |
|
Ubis (Asia) Public Company Limited
BK:UBIS
|
0.047x |
Annual Cash Flow Conversion Efficiency for Active Biotech AB (2002–2024)
The table below shows the annual cash flow conversion efficiency of Active Biotech AB from 2002 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr32.07 Million | Skr-40.40 Million | -1.260x | +15.54% |
| 2023-12-31 | Skr30.67 Million | Skr-45.74 Million | -1.492x | +6.15% |
| 2022-12-31 | Skr34.51 Million | Skr-54.85 Million | -1.589x | -60.68% |
| 2021-12-31 | Skr46.67 Million | Skr-46.17 Million | -0.989x | +32.11% |
| 2020-12-31 | Skr22.11 Million | Skr-32.22 Million | -1.457x | -118.79% |
| 2019-12-31 | Skr53.78 Million | Skr-35.81 Million | -0.666x | -44.02% |
| 2018-12-31 | Skr87.92 Million | Skr-40.65 Million | -0.462x | +22.68% |
| 2017-12-31 | Skr77.68 Million | Skr-46.45 Million | -0.598x | -49.20% |
| 2016-12-31 | Skr182.56 Million | Skr-73.16 Million | -0.401x | +66.78% |
| 2015-12-31 | Skr180.60 Million | Skr-217.89 Million | -1.206x | -83.08% |
| 2014-12-31 | Skr405.31 Million | Skr-267.09 Million | -0.659x | -161.28% |
| 2013-12-31 | Skr405.41 Million | Skr-102.25 Million | -0.252x | +64.34% |
| 2012-12-31 | Skr339.92 Million | Skr-240.40 Million | -0.707x | -655.82% |
| 2011-12-31 | Skr501.99 Million | Skr-46.97 Million | -0.094x | +91.34% |
| 2010-12-31 | Skr181.76 Million | Skr-196.32 Million | -1.080x | +9.35% |
| 2009-12-31 | Skr188.64 Million | Skr-224.77 Million | -1.192x | -22.25% |
| 2008-12-31 | Skr163.61 Million | Skr-159.46 Million | -0.975x | +1.04% |
| 2007-12-31 | Skr189.57 Million | Skr-186.70 Million | -0.985x | +40.63% |
| 2006-12-31 | Skr60.36 Million | Skr-100.13 Million | -1.659x | -52.37% |
| 2005-12-31 | Skr176.81 Million | Skr-192.51 Million | -1.089x | -18.08% |
| 2004-12-31 | Skr162.30 Million | Skr-149.65 Million | -0.922x | +7.56% |
| 2003-12-31 | Skr289.58 Million | Skr-288.83 Million | -0.997x | -30.02% |
| 2002-12-31 | Skr380.27 Million | Skr-291.71 Million | -0.767x | -- |